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Well differentiated neuroendocrine tumours or carcinoids
include a spectrum of neoplasms originating in the neuroendocrine
cells of the diffuse neuroendocrine system and sometimes
producing a number of biologically active agents (Solcia et al,
2000b). Their clinical behaviour is hardly predictable on the basis
of conventional clinico-pathological criteria (Läuffer et al, 1999).
In addition, little or no information is available regarding their
pathogenesis, with the notable exception of gastric carcinoids for
which a role of hypergastrinemia has been suggested (Solcia et al,
2000b).
Most information on the epidemiology of neuroendocrine
tumours comes from clinical and pathological series. A cancer
registration-based dataset including 3382 malignant or ‘uncertain
behaviour’ cases from England and Wales and 639 from Scotland
over the period 1979–89 reported incidence rates around
1/100 000, with a female excess mainly in reproductive years,
which could be partly but not totally accounted for better diagnosis
and ascertainment (Newton et al, 1994). Further, a comprehensive
report included 8305 cases of malignant carcinoid tumours regis-
tered in the Surveillance, Epidemiology and End Results (SEER)
program of the National Cancer Institute (NCI), and in two
previous NCI programs (Modlin and Sandor, 1997). In that series,
carcinoid incidence rates were higher in females than in males, a
noticeable proportion was associated with other neoplasms, the
most frequent sites were the gastrointestinal tract, followed by
lung, the overall five-year relative survival rate was over 50%, and
the incidence of the disease had increased over the last 20 years.
We have updated our report on descriptive epidemiology and
survival of carcinoids in the Swiss Canton of Vaud over the period
1974–97, the major population-based series from Continental
Europe (Levi et al, 1993).
The data were derived from the Vaud Cancer Registry datafile,
which includes data concerning incident cases of malignant
neoplasms and selected non-malignant or pre-cancerous lesions,
diagnosed in the resident population of the Canton (whose
population in 1990 was about 570 000 inhabitants; Levi et al,
1997). Information collected by the register includes general
characteristics of the patient (age, sex), site and histological type
of the tumour according to the standard International
Classification of Diseases for Oncology (ICD-O, Ninth Revision;
World Health Organization, 1976), and time of registration. Age-
standardized rates were computed by the direct method, on the
basis of the world standard population (Doll and Smith, 1987).
Passive and active follow-up information is recorded, and each
subsequent item of information concerning an already registered
case is used to complete the corresponding record. Information
coming from death certificates is routinely added to the
incidence file. Information on vital status is derived, for
‘apparently’ non-deceased cases, from the registries of current
residence.
The present series comprises 218 first malignant (i.e., locally
infiltrating/metastastising; Levi et al, 1991, 1993) (118 males,
100 females), and 215 benign (77 males, 138 females) carcinoids
registered from 1974 to 1997 in the resident population of the
Canton. Only first occurrences were considered. In accord with the
ICD-O classification (World Health Organization, 1976), the
great majority of carcinoids diagnosed in the lung (ICD-O-M
morphology code: 8240) were considered as malignant (fifth digit
of ICD-O-M code: ³3). Histological confirmation was 100%.
The vital status of each case considered for the present analysis
was verified up to December 31, 1999. Twenty malignant cases
(9%) and 22 benign cases (10%), discovered at autopsy, were not
considered for survival analysis. Losses to follow-up were about
7%. Complete information on five-year survival was available for
343 (79%) uncensored cases and was computed starting from the
date of histological confirmation. Relative survival rates (Ederer
et al, 1961) were computed after allowance for the general
lifetables of the canton (Levi et al, 1992).
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Table 1 gives the distribution of 433 cases of carcinoids
according to sex, site, calendar period and histological type.
Overall, age standardized incidence rates for both sexes and all
sites combined rose from 19.6/106 in 1974–85 to 28.2/106 in
1986–97. The rise was apparently larger in males (from 15.2 to
29.3/106) than in females (from 24.8 to 28.2/106), in the absence of
any clear pattern across sites. Further, the upward trends over time
were apparently larger for malignant (from 7.7 to 13.9/106) than
for benign (from 11.9 to 14.3/106) neoplasms.
Colorectum was the most common site (n = 174, 40%),
followed by small intestine (n = 116, 27%), lung (n = 79, 18%),
and stomach (n = 19, 4%), (Table 1). Lung was the most common
site for malignant carcinoids, and intestines (mainly colorectum)
for benign ones, while less than 5% of benign carcinoids were
outside digestive tract. Overall, 141 out of 174 (81%) tumours of
the colorectum were benign, and 14 out of 19 (74%) gastric
tumours. Conversely, only 44 out of 116 (38%) tumours of the
small intestine were benign and only five out of 79 (6%) in the
lung. The upward trends over time were somewhat larger for small
intestines and other sites, but they were observed across all
separate sites.
Figure 1 gives age-specific incidence rates for malignant,
benign carcinoids, and separately for digestive tract and lung for
malignant cases. The incidence rates rose with age both for
malignant and benign cases, particularly for digestive tract (from
stomach to rectum).
Table 2 gives survival rates for malignant carcinoids in two
calendar periods 1974–85, and 1986–97. Five-year relative
survival increased from 0.64 to 0.75 for males and from 0.73 to
0.83 for females and in both sexes, was highest for lung, followed
by digestive tract.
Sixty-eight subjects (16% of all carcinoids; 35 malignant, 33
benign) had another either synchronous (i.e. diagnosed less than
three months after the first primary tumour; n = 51) or metachro-
nous (n = 17) malignant non carcinoid non cutaneous (excluding
non-melanomatous skin) neoplasm. Two additional subjects were
registered with two intestinal primary carcinoids (two malignant
synchronous carcinoids, one of the small bowel and one of the
caecum; one benign and one malignant metachronous rectal carci-
noid in the other subject). Of the 51 synchronous tumours, 18 were
in the digestive tract, nine in the lung, and 24 in various combina-
tions of sites. Of the 17 metachronous tumours, only one was in
the digestive tract, and among the remaining 16 second primary
non carcinoid neoplasms two lung, five breast, two prostate, and
one oral cavity, intestines, bladder, kidney, brain, lymphoid, and
haemopoietic tissue. The number of metachronous neoplasms was
however lower than the expected one (i.e., 17 cases observed
versus 27.3 expected; standardized incidence ratio = 0.62, 95%
confidence interval: 0.36–1.00).
The present work confirms, in a uniformly surveyed population,
that carcinoids are rare – but not extremely rare – neoplasms, with
overall age-standardized rates around 1/100 000 for both benign
and malignant carcinoids. Malignant carcinoids were about 40%
more common in males than in females, whereas benign ones were
about two-fold more common in females (Rindi et al, 1996). This
may reflect greater opportunities for diagnosis particularly for
abdominal carcinoids in females following laparotomies in repro-
ductive age or for other conditions (e.g. gallstones) more common
in females (Thompson et al, 1985; Newton et al, 1994). An influ-
ence of sex hormones on (benign) carcinoids cannot be excluded,
in view of the reported presence of oestrogen receptor proteins
(Keshgegian and Wheeler, 1980). Female predominance has also
Table 1 Absolute numbers and age-adjusted incidence rates (rates per million, world standard population) of malignant and benign carcinoid tumours
according to sex, calendar period and anatomical site. Vaud, Switzerland, 1974–1997
Primary site Males Females Males and Females
74–85 86–97 Total 74–85 86–97 Total 74–85 86–97 Total
n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate
Malignant
carcinoids
Stomach 1 0.3 3 0.7 4 0.5 0 – 1 0.2 1 0.1 1 0.1 4 0.5 5 0.3
Small intestine 11 2.3 31 5.8 42 4.1 10 1.2 20 3.5 30 2.4 21 1.6 51 4.4 72 3.1
Colorectum 4 1.3 10 2.6 14 1.9 9 2.7 10 2.2 19 2.4 13 2.0 20 2.3 33 2.1
Lung 12 3.2 25 5.8 37 4.6 15 3.5 22 3.6 37 3.5 27 3.3 47 4.7 74 4.0
Other 6 1.3 15 2.6 21 2.0 2 0.2 11 1.7 13 1.0 8 0.6 26 2.0 34 1.4
Total, all sites 34 8.4 84 17.6 118 13.1 36 7.7 64 11.1 100 9.4 70 7.7 148 13.9 218 10.9
Benign
carcinoids
Stomach 2 0.4 4 1.0 6 0.7 5 0.6 3 0.1 8 0.4 7 0.5 7 0.6 14 0.6
Small intestine 15 3.1 17 3.1 32 3.1 4 0.3 8 0.9 12 0.7 19 1.5 25 1.9 44 1.7
Colorectum 13 3.2 23 7.2 36 5.2 50 15.0 55 14.8 105 14.9 63 9.2 78 11.0 141 10.1
Lung 1 0.1 0 – 1 0.1 3 0.7 1 0.2 4 0.5 4 0.4 1 0.1 5 0.3
Other – – 2 0.4 2 0.2 2 0.4 7 1.0 9 0.7 2 0.2 9 0.7 11 0.5
Total, all sites 31 6.8 46 11.7 77 9.2 64 17.2 74 17.1 138 17.1 95 11.9 120 14.3 215 13.1
Benign and
malignant
carcinoids
Stomach 3 0.7 7 1.7 10 1.2 5 0.6 4 0.3 9 0.5 8 0.7 11 1.0 19 0.9
Small intestine 26 5.4 48 9.0 74 7.2 14 1.6 28 4.4 42 3.1 40 3.1 76 6.3 116 4.8
Colorectum 17 4.5 33 9.8 50 7.1 59 17.7 65 17.0 124 17.3 76 11.2 98 13.4 174 12.2
Lung 13 3.3 25 5.8 38 4.6 18 4.3 23 3.8 41 4.0 31 3.7 48 4.8 79 4.3
Other 6 1.3 17 3.0 23 2.3 4 0.6 18 2.7 22 1.7 10 0.9 35 2.7 45 1.9
Total, all sites 65 15.2 130 29.3 195 22.4 100 24.8 138 28.2 238 26.5 165 19.6 268 28.2 433 24.0954 F Levi et al
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been observed in an African rodent model of gastric carcinoids
(Modlin et al, 1994; Modlin and Sander, 1997).
The site distribution of carcinoids confirms that carcinoids are
commonest in the colorectum, followed by small intestine, lung,
and stomach.
Benign tumours were observed mainly in the colon and
stomach, as in pathological series (Fiocca et al, 1987; Rindi et al,
1996). This finding may well reflect the early symptomatic
features of the frequently polypoid carcinoids of the upper and
lower digestive tract, as well with their relatively straightforward
investigation and treatment. Most tumours of the small intestine
and lung were classified as malignant. Differences in the cell
biology of tumours from different sites cannot be excluded.
Over the two calendar periods considered (1974–85 and
1986–97), incidence rates of benign carcinoids in both sexes
combined increased by about 20%, whears malignant neoplasms
almost doubled. The largest proportional rises in incidence were
observed for stomach and small intestine. These upward trends
may be related to diagnostic improvements during the last decade,
following the widespread use of specific markers in pathology
practice, and the introduction of somatostatin analogs for imaging
procedures (Krenning et al, 1999; Solcia et al, 2000a). An influ-
ence of diagnostic improvements in malignant carcinoids is indi-
cated by the observed increased survival over time. For gastric
carcinoids, this rise in incidence would be consistent with the
introduction and subsequent widespread use of powerful acid
inhibitory drugs which stimulate gastric secretion (Mignon et al,
1987; Rindi et al, 1996). The latter has been shown in animal
models to increase malignant gastric carcinoids (Larsson et al,
1986; Modlin et al, 1988, 1989; Läuffer et al, 1999). However, no
information on drug use was available in the Vaud cancer register.
With reference to the age distribution, this study confirms
(Newton et al, 1994; Modlin and Sandor, 1997) that the incidence
of both benign and malignant carcinoids increases with age, like
Malignant carcinoid tumours
Benign carcinoid tumours
Males
Females
Age group
5– 15– 25– 35– 45– 55– 65– 75– 85+
Age group
5– 15– 25– 35– 45– 55– 65– 75– 85+
Age group
5– 15– 25– 35– 45– 55– 65– 75– 85+
200
150
100
50
0
R
a
t
e
 
p
e
r
 
m
i
l
l
i
o
n
80
60
40
20
0
R
a
t
e
 
p
e
r
 
m
i
l
l
i
o
n
R
a
t
e
 
p
e
r
 
m
i
l
l
i
o
n
Digestive
Lung
Males
Females
40
30
20
10
 0
Malignant carcinoid tumours, males & females
Figure 1 Age-specific incidence curves (rates per million per years) by sex for malignant and benign carcinoids, and by site, both sexes combined, for
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most epithelial neoplasms, the levelling off for benign ones above
age 80 being partly or largely attributable to diagnostic difficulties
in the elderly.
The overall survival rate of 76% is appreciably greater than the
50% reported in the SEER dataset. However, absolute rather than
relative survival was given by the SEER dataset.
This study also confirms (Berner, 1993) that a substantial
proportion carcinoids was associated with other synchronous
neoplasms. This proportion is similar to that observed in the SEER
database (13%; Modlin and Sandor, 1997). The lower than
expected number of metachronous neoplasms suggests that at
least part of the excess of second neoplasms in patients with carci-
noids is attributable to careful diagnostic ascertainment at original
diagnosis.
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